Hungary Is Hungry for EO

Medistri launches its second EO sterilization line in Hungary, building certified capacity for Europe's fast-growing medical device sector

18 May 2026

Medistri, which describes itself as Europe's largest independent sterilization provider, has commissioned a second ethylene oxide line at its facility in Hungary, a project valued at $2.5 million and completed over eighteen months. The expansion responds to rising demand for compliant sterilization services across the continent, where hospital procurement of single-use medical devices has grown considerably in recent years.

Ethylene oxide occupies a singular role in the sterilization industry. The compound accounts for nearly half of all single-use medical device sterilization globally, according to industry estimates, penetrating complex geometries and heat-sensitive materials that steam or radiation cannot safely treat. Surgical kits, catheters, and implants depend on it. As European hospitals increase surgical volumes and integrate more disposable equipment, analysts have said compliant EO capacity has struggled to keep pace with demand.

The Hungarian site, which opened in January 2025 following a $4 million initial investment, holds ISO 13485 certification and was built to process 15,000 pallets annually. Expanding within an already certified facility carries strategic value for Medistri's clients, who would otherwise face a re-validation process spanning six to eighteen months of product qualification, regulatory filings, and audit cycles when changing sterilization partners.

Regulatory and environmental pressures have added further complexity to the sector. New European Union guidance has formally brought EO sterilization within the scope of the Medical Device Regulation and the In Vitro Diagnostic Regulation, raising documentation and conformity assessment requirements throughout the supply chain. Yet European agencies also classify ethylene oxide as carcinogenic and toxic for reproduction, placing operators under concurrent pressure to expand emissions abatement alongside capacity. Medistri's integrated model, combining laboratory services, packaging validation, and manufacturing under one quality system, is intended, company statements suggest, to consolidate compliance management for clients.

Global sterilization services are projected to reach $5.81 billion in 2026, advancing toward $8 billion by 2030 at an annual rate of roughly 8 percent. How companies position themselves within that growth, and under what environmental conditions, could shape both regulatory frameworks and supply chain strategies for the European medtech sector in the years ahead.